Research Program G: Translational Cancer Research

© dkfz.de

Below you will find DKFZ divisions and research groups of the Research Program Translational Cancer Research who are interested in recruiting Postdocs within the 2018 DKFZ Postdoctoral Fellowships Selection.

Please note that this is not an exhaustive list and new groups are continously added.

You may also contact the principal investigator of the DKFZ research group of your choice directly to discuss about current possibilities. More information about hiring labs can be found below and descriptions of DKFZ research programs via the general topic locator.

< BACK to overview page

Applied Bioinformatics – Prof. Dr. Benedikt Brors

© dkfz.de

RESEARCH PROFILE

The Division Applied Bioinformatics at DKFZ and NCT develops computational methods to predict optimal therapeutic regimes to cancer patients based on comprehensive profiles of genetic, transcriptomic and epigenetic alterations in tumors (https://www.nct-heidelberg.de/en/research/nct-master.html). We are also studying large cohorts of cancer patients in the context of big international collaborations like the Pan Cancer Analysis of Whole Genomes project (ICGC-PCAWG, https://dcc.icgc.org/pcawg).

 

PROJECT TOPICS

Methodologically, we include now methods from immunoinformatics and single-cell analysis. If you are interested in tumor biology, cancer heterogeneity and evolution or in precision oncology and have some affinity to work with computers you should definitely connect to us.

Please visit our website for further information on our research and recent publications. 

LINK: http://www.dkfz.de/en/applied-bioinformatics/index.php

Neuroimmunology and Brain Tumor Immunology – Prof. Dr. med. Michael Platten

© dkfz.de

RESEARCH PROFILE

The central nervous system (CNS) is considered an immune privileged organ, where immune responses are tightly controlled through an intensive cross-talk with the peripheral immune system despite the blood-brain barrier. Yet, a hallmark of intrinsic CNS tumors like gliomas is active immunosuppression.
Our main research interest is the discovery of novel target antigens and immunomodulators for immunotherapy of gliomas. To test immunogenicity of a specific mutation, we have developed an MHC-humanized syngeneic mouse tumor model and established a novel method to detect the immunological presentation of the mutated antigen in patient brain tumor tissue. With these tools, we identified specific spontaneous immune responses in brain tumor patients and therapeutic efficacy of a specific vaccine in preclinical studies. On this basis, a phase I clinical study to test immunogenicity and tolerability of this vaccine in brain tumor patients has completed follow-up for all patients in Q3 2017.

PROJECT TOPICS

Ongoing and future projects deal with (a) the mode of action of the vaccine in the mouse model and study patients, (b) the identification of individual and shared neoepitopes in brain tumors for specific immunotherapy, (c) the recognition of glioma-specific T cell receptors (TCR) for adoptive T cell transfer therapy, (d) conceptual combination with other immunotherapeutic interventions such as immune checkpoint blockers in brain tumors, and (e) analyses of immunosuppressive glioma microenvironmental factors.

Please visit our website for further information on our research and recent publications.

LINK: http://www.dkfz.de/en/neuroimmunologie/index.php

to top